Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a evaluation of long-term follow-up results

Clinical Drug Investigation

Volumn 25, Issue 10, 2005, Pages 661-667

  Bostanci, Seher ^a   Kocyigit, Pelin ^a   Alp, Ayşegül ^a   Erdem, Cengizhan ^a   Gürgey, Erbak G ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; LONG TERM CARE; MALE; MOOD DISORDER; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 24944590701     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525100-00005     Document Type: Article

References (32)

1. Miller SJ. Biology of basal cell carcinoma (Part I). J Am Acad Dermatol 1991; 24: 1-13
2. Fleming ID, Amonette R, Monaghan T, et al. Principles of management of basal and squamous cell carcinoma of the skin. Cancer 1995; 75: 699-704
3. Friedman RJ, Rigel DS, Kopf AW, et al. Cancer of the skin. 1st ed. Philadelphia (PA): WB Saunders Company, 1991: 35-73
4. Swanson N. Mohs' surgery. Arch Dermatol 1983; 119: 761-73
5. Limmer BL, Clark D. Nonsurgical management of primary skin malignancies. Otolaryngol Clin North Am 1993; 26: 167-83
6. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987; 14: 1-12
7. Wickramasinghe L, Hindson TC, Wacks H. Treatment of neo-plastic skin lesions with intralesional interferon. J Am Acad Dermatol 1989; 20: 71-4
8. Greenway HT, Cornell RC, Taner DJ, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986; 15: 437-43
9. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700
10. Thestrup-Pedersen K, Jacobsen IE, Frentz G. Intralesional in-terferon alfa 2b treatment for basal cell carcinoma. Acta Derm Venereol 1990; 70: 512-4
11. Boneschi V, Brambilla L, Mozannica N, et al. Treatment of basal cell carcinomas with intralesional alpha-2b recombinant interferon. J Invest Dermatol 1989; 93: 542-3
12. Boneschi V, Brambilla L, Chiappino G, et al. Intralesional alpha-2b recombinant interferon for basal cell carcinomas. Int J Dermatol 1991; 30: 220-4
13. Healsmith MF, Berth-Jones J, Fletcher A, et al. Treatment of basal cell carcinoma with intralesional interferon alpha-2b. J R Soc Med 1991; 84: 524-6
14. Pizarro A, Fonseca E. Treatment of basal cell carcinoma with intralesional interferon alpha-2b: evaluation of efficacy with emphasis on tumors located on 'H' zone of the face. Eur J Dermatol 1994; 4: 287-90
15. LeGrice P, Baird E, Hodge L. Treatment of basal cell carcinoma with intralesional interferon alpha-2A. N Z Med J 1995; 108: 206-7
16. Grob JJ, Collet AM, Munoz MH, et al. Treatment of large basal cell carcinomas with intralesional interferon-alpha 2a. Lancet 1988; I: 878-9
17. Dogan B, Harmanyeri Y, Baloglu H, et al. Intralesional alfa-2a interferon therapy for basal cell carcinoma. Cancer Lett 1995; 91: 215-9
18. Alpsoy E, Yilmaz E, Başaran E, et al. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol 1996; 23: 394-6
19. Chimenti S, Peris K, Di Cristofaro S, et al. Use of recombinant interferon alpha-2b in the treatment of basal cell carcinoma. Dermatology 1995; 190: 214-7
20. Di Lorenzo PA, Goodman N, Lansville F, et al. Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-2b. J Am Acad Dermatol 1994; 31: 109-11
21. Stenquist B, Wennberg AM, Gisslen H, et al. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs' surgery. J Am Acad Dermatol 1992; 27: 65-9
22. Buechner S, Wernli M, Bachmann F, et al. Intralesional interfer-on in basal cell carcinoma: how does it work? Recent Results Cancer Res 2002; 160: 246-50
23. Mozzanica N, Cattaneo A, Boneschi V, et al. Immunohistologi-cal evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha-2 interferon. Arch Dermatol 1990; 282: 311-7
24. Tyring SK. Antitumor actions of interferon: direct, indirect and synergy with other treatment modalities. Int J Dermatol 1987; 26: 579-86
25. Belardelli F, Ferrantini M, Proietti E, et al. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119-34
26. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumors: part 1. BioDrugs 2002; 16 (4): 261-81
27. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003 Mar 19; 95 (6): 437-48
28. Wu WZ, Sun HC, Shen YF, et al. Interferon alpha 2a downregu-lates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 2005; 131: 169-78
29. Dunn GP, Bruce AT, Sheehan KCF, et al. A critical function for type 1 interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-9
30. Kowalzick L, Rogozinski T, Wimheuer R, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open label multicenter study. Eur J Dermatol 2002; 12: 558-61
31. McDaniel WE. Adequate follow-up for basal cell carcinoma. Arch Dermatol 1986; 122: 243-4
32. Carter DM, Lin AN. Basal cell carcinoma. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general medicine. 4th ed. Boston (MA): McGraw Hill Inc, 1993: 840-847